Receives multiple Best in KLAS awards in Claims Management & Clearinghouse and Patient Access LEHI, Utah and LOUISVILLE, Ky., Feb. 5, 2025 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today announced its top ranking in multiple 2025 Best in KLAS categories: Claims Management & Clearinghouse and Patient Access. Based on independent client feedback, these recognitions underscore the value healthcare providers gain from Waystar's AI-powered software pl ...

GRAND CAYMAN, Cayman Islands, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Oxbridge Re Holdings Limited (Nasdaq: OXBR) ("Oxbridge Re"), together with its subsidiary SurancePlus, is engaged in the tokenization of Real-World Assets ("RWAs"), initially with tokenized reinsurance securities, and in providing reinsurance solutions to property and casualty insurers in the Gulf Coast region of the United States, today announced it has selected Coinbase Prime to facilitate its investments in other digital assets as part of it ...

MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that the first two patients have been entered into the pivotal Phase 3 study evaluating buntanetap in early AD. "The launch of our highly anticipated AD study is a significant milestone in advancing bunt ...

HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Systemic Bio™, a 3D Systems company (NYSE: DDD), has been named the winner of the prestigious SLAS 2025 Innovation Award. This award recognizes groundbreaking technological advancements poised to drive innovation in laboratory science and automation. The competition featured cutting-edge developments led by distinguished experts from top institutions worldwide. The award highlights Systemic Bio’s proprietary h-VIOS™ platform, designed to accelerate drug discovery a ...

Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development (“R&D”) collaborations aligned with Orchestra BioMed’s partnership-enabled business model Mr. Cleary previously served as Senior Vice President (“SVP”) of Corporate Development at Medtronic plc (NYSE: MDT) (“Medtronic”), where he played a key role in establishing the strategic collaboration between Orchestra BioMed and Medtronic for atrioventricular interval modulation (“AVIM”) thera ...

-- Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose Approximately Nine Months Later -- -- VAX-31 is Designed to Cover Approximately 94% of Invasive Pneumococcal Disease and Approximately 93% of Acute Otitis Media in U.S. Children Under Five -- -- Company Remains ...

Safety Committee approval based on positive Phase 1 safety data demonstrating the combination therapy to be generally well-tolerated with no severe treatment-related adverse events or dose-limiting toxicities Enrollment for Phase 2 expected to commence imminently OCALA, Fla., Feb. 05, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced Safety Committee approval to proceed with the Phase 2 portion of the Phase 1b/2 clinical trial involving AIM's Ampligen® (rintato ...

SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, extends its sincere congratulations to Dr. Tessa Cigler, esteemed Board Director at Atossa and Associate Professor of Clinical Medicine at Weill Cornell Medicine, and the Weill Cornell Medicine team for being awarded a five-year, $2.3 million grant from the Centers for Disease Control and Prevent ...

Lifeward signs contractual agreement with BARMER, Germany's second largest statutory health insurance company, to streamline access to ReWalk Personal Exoskeletons for eligible beneficiaries Following this agreement, approximately 45% of people with Statutory Health Insurance in Germany now have coverage policies with a defined reimbursement process for personal exoskeletons MARLBOROUGH, Mass. and BERLIN, Germany, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), ...

Customers Say R1’s Focus on Delivering Innovation & Expertise is Solving Healthcare ChallengesMURRAY, Utah, Feb. 05, 2025 (GLOBE NEWSWIRE) -- R1 RCM Inc. (“R1”), a leader in technology-driven healthcare solutions, has been named a 2025 ‘Best in KLAS’ award winner in several key categories, underscoring its capabilities in revenue cycle management through cutting-edge technology and core expertise. This recognition highlights R1’s commitment to delivering innovative solutions and exceptional results for heal ...